10-30-08

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No. : 10/525,986

Applicants

: Tadashi NAKAJIMA et al.

Filed

: February 25, 2005

For

7 2 9 2008

: THERAPEUTIC AGENT FOR

GLAUCOMA COMPRISING Rho

KINASE INHIBITOR AND

PROSTAGLANDIN

Art Unit

: 4161

Examiner

: Sean M. BASQUILL

Docket No. : 05116/HG

Confirm. No.: 5004

Customer No.: 01933

AMENDMENT UNDER 37 CFR 1.111

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

MAIL STOP AMENDMENT

SIR:

This is in response to the Office Action mailed July 29, 2008, the term for response to which is set to expire on October 29, 2008. Please amend the above-identified application as follows:

Amendments to the Specification are set forth on page 2 of this paper. Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Amendments to the Abstract are set forth on page 10 of this paper. Remarks begin on page 11 of this paper.

A SUBSTITUTE SPECIFICATION is attached following the last page of this paper.

Express Mail Mailing Label No.: EM 361 416 915 US

Date of Deposit: October 29, 2008 I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 with sufficient postage on the date indicated above and is

addressed to: MAIL STOP AMENDMENT Commissioner for Patents.

P.O. Box 1450

Alexandria, VA 22313-1450

In the event that this Paper is late filed, and the necessary petition for extension of time is not filed concurrently herewith, please consider this as a Petition for the requisite extension of time, and to the extent not tendered by Form PTO-2038 attached hereto, authorization to charge the extension fee, or any other fee required in connection with this Paper to Account No. 06-1378.